Ivan Kairatov is a biopharma expert with a track record bridging preclinical discovery and translational development across oncology subtypes. He has worked at the interface of receptor biology, pharmacology, and clinical trial design, and he brings a pragmatic lens to drug repurposing. In this
Could a single seed pull double duty against inflammation, oxidative stress, microbes, and metabolic drift without the side-effect ledger that shadows many prescriptions, and could it do so in a way that complements rather than competes with standard care? That is the provocation driving a surge of
In a world where a stroke strikes someone every 40 seconds, the fear of a second, potentially fatal event looms large for millions of survivors, creating an urgent need for better solutions. Picture a patient, just recovered from an initial stroke, grappling with the uncertainty of whether their
In a world where Alzheimer’s disease continues to challenge medical science with its relentless progression and devastating impact on millions of lives, the search for effective treatments remains a top priority for researchers and pharmaceutical companies alike. Recent developments have sparked
I'm thrilled to sit down with Dr. Ivan Kairatov, a renowned expert in pediatric medicine with a focus on liver transplantation and patient-reported outcomes. With years of experience in research and innovation, Dr. Kairatov has been at the forefront of shifting how we understand children's
Imagine a silent epidemic affecting thousands of men each year, often undetected until it’s too late, with societal norms discouraging open conversations about personal health challenges, and prostate cancer standing as the most common cancer among men in the UK, with around 55,000 new cases
